About Baergic Bio
Baergic Bio is a Healthcare company based in New York (United States) founded in 2019, and was acquired by Axsome Therapeutics in November 2025. Novel therapeutics for CNS disorders are developed and commercialized. Its chief executive, as recorded, is Lindsay Rosenwald. Baergic Bio offers products and services including AJ201, BAER-101, and IV Tramadol. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Avenue Therapeutics, Inc. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Baergic Bio was founded in 2019 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where novel therapeutics for central nervous system (CNS) disorders are developed and commercialized. Emphasis is placed on compounds such as BAER-101, a selective GABA_A positive allosteric modulator, which is evaluated in clinical and preclinical studies for areas of unmet medical need. The companys domain is baergicbio.com.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website baergicbio.com
- Social LinkedIn X
- Acquired by Avenue Therapeutics (Nov 2022)
- Legal Name Avenue Therapeutics, Inc.
- InvestorsAxsome Therapeutics
& 1 more
- Acquired by
Products & Services of Baergic Bio
Baergic Bio offers a comprehensive portfolio of products and services, including AJ201, BAER-101, and IV Tramadol.
Drug in development for treating neurologic diseases.
Therapy aimed at addressing specific neurologic conditions.
Intravenous drug for pain relief in neurologic contexts.
Investors in Baergic Bio
Baergic Bio has secured backing from 2 investors. Prominent investors backing the company include Axsome Therapeutics and Avenue Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. | 2015 | avenuetx.com | New York, United States | |
Therapeutics for CNS disorders are developed by Axsome Therapeutics. | 2012 | axsome.com | New York, United States |
Investor details for Baergic Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Baergic Bio
1 people are tracked at Baergic Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Lindsay Rosenwald | CEO | Leadership |
Complete people profiles for Baergic Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Baergic Bio
3 dated milestones of Baergic Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Baergic Bio is founded.
- Exit Acquired by Avenue Therapeutics.
- Exit Acquired by Axsome Therapeutics.
Competitors of Baergic Bio
Baergic Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Baergic Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Baergic Bio (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Baergic Bio
Complete news archive for Baergic Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Baergic Bio
Baergic Bio was founded in 2019.
Baergic Bio is headquartered in New York, United States. It is registered at New York, New York, United States.
Lindsay Rosenwald is the CEO of Baergic Bio, as recorded in our data.
Baergic Bio was founded in 2019 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where novel therapeutics for central nervous system (CNS) disorders are developed and commercialized. Emphasis is placed on compounds such as BAER-101, a selective GABA_A positive allosteric modulator, which is evaluated in clinical and preclinical studies for areas of unmet medical need. The companys domain is baergicbio.com.
Baergic Bio's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Baergic Bio offers AJ201, BAER-101, and IV Tramadol.
Baergic Bio has 2 investors. Key investors include Axsome Therapeutics, and Avenue Therapeutics.
Baergic Bio operates through Avenue Therapeutics, Inc..
Yes. Baergic Bio was acquired by Avenue Therapeutics in November 2022.